Home \ Research \ Scientific publications \


Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial

Investigation article published in BMC Veterinary Research

March 10th, 2016

BACKGROUND:
Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing chondroitin sulfate (CS) and prebiotics (resistant starch, β-glucans and mannaoligosaccharides) was developed to target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180 days administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut microbiota, and serum biomarkers of inflammation and oxidative stress.
RESULTS:
Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant differences between groups (p > 0.05) for any of the studied parameters. Final data analysis (supplement: n = 9; placebo: n = 10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after treatment (p < 0.001). After treatment, a significant decrease (1.53-fold; p < 0.01) in histologic score was seen only in the supplement group. When groups were compared, the supplement group showed significantly higher serum cholesterol (p < 0.05) and paraoxonase-1 (PON1) levels after 60 days of treatment (p < 0.01), and the placebo group showed significantly reduced serum total antioxidant capacity (TAC) levels after 120 days (p < 0.05). No significant differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group.
CONCLUSIONS:
The combined administration of the supplement with hydrolyzed diet over 180 days was safe and induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to dietary treatment of this supplement on intestinal histology and CIBDAI




Segarra S., Martinez-Subiela S., Cerda-Cuellar M., Martinez-Puig D., Munoz-Prieto A., Rodriguez-Franco F., Rodriguez-Bertos A., Allenspach K., Velasco-Franco A. and Ceron J.




See this article
Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial

See it on NLM PubMed
Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial



Participants:

R&D Bioiberica.

Universidad de MurciaCampus de Excelencia Mare Nostrum. Universidad de Murcia (UM).

Universidad de MurciaDepartamento de Medicina y Cirugía Animal. Facultad de Veterinaria. Universidad de Murcia (UM).

Universitat Autònoma de BarcelonaCentre de Recerca en Sanitat Animal (CReSA). Universitat Autònoma de Barcelona (UAB).

Generalitat de CatalunyaInstituto de Investigación y Tecnología Agroalimentarias (IRTA). Generalitat de Catalunya.

Universidad ComplutenseDepartamento de Medicina y Cirugía Animal. Facultad de Veterinaria. Universidad Complutense (UCM).

Universidad ComplutenseServicio de Patología y Veterinaria Forense (SAP). Centro de Vigilancia Sanitaria Veterinaria (VISAVET). Universidad Complutense (UCM).

University of LondonDepartment of Veterinary Clinical Sciences and Services. Royal Veterinary College. University of London.







BMC Veterinary Research
FACTOR YEAR Q
1.750 2016

NLMID: 101249759

PMID: 26965834

ISSN: 1746-6148



TITLE: Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial


JOURNAL: BMC Vet Res


NUMERACIÓN: 12(1):49


AÑO: 2016


PUBLISHER: BioMed Central


AUTHORS: Segarra S., Martinez-Subiela S., Cerda-Cuellar M., Martinez-Puig D., Munoz-Prieto A., Rodriguez-Franco F., Rodriguez-Bertos A., Allenspach K., Velasco-Franco A. and Ceron J.


Antonio Manuel Rodríguez Bertos

DOI: https://doi.org/10.1186/s12917-016-0676-x


CITE THIS PUBLICATION:

Segarra S., Martinez-Subiela S., Cerda-Cuellar M., Martinez-Puig D., Munoz-Prieto A., Rodriguez-Franco F., Rodriguez-Bertos A., Allenspach K., Velasco-Franco A. and Ceron J. Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial. BMC Veterinary Research. 12(1):49. 2016. (A). ISSN: 1746-6148. DOI: 10.1186/s12917-016-0676-x


UNITS: